SERVICES
Great bonds make Great Proteins.
Integrated services to ____ your molecule from gene ________ to potential drug candidate. ______ multiple host systems - _________, yeast and mammalian.

In the trial version of Web2Disk every fifth word is blanked out. To copy this site with all the words, please upgrade to the full version and copy this website again.
Integrated services to ____ your molecule from gene ________ to potential drug candidate. ______ multiple host systems - _________, yeast and mammalian.
ABio-therapeutic development programs, _________ creation of protein candidates ___ antibody molecules requires extensive _______ on physiochemical and biological ________ characterization.
Success for any _________ lies in its ability __ demonstrate potency, efficacy and ______ in the Clinic. Our _____________ lab at Premas is _______ in building this foundation ___ the bio-therapeutic molecules we _______ and support through their _______ in late stages. We __________ the involvement it takes, ___ have deep understanding of ___ engagement and the diligence ________.
For Biophysical characterisation __ the molecules, we have ___________ a portfolio of studies __ understand the identification parameters, ______ and impurity profile, concentration ___ aggregation issues and stability ____.
Functional characterization is _________ relating to biological properties __ the molecules including development ___ conducting assays as ELISA, ______ assays, bioassays as neutralization ________, proliferation assays, CDC and ____.
Throughout the development _______ for a biological candidate, ___ processes at Premas strictly ______ to the guidelines laid __ EMEA, ICH and CDSCO, _______ in account the geography ____ the molecule is being ________ for.
Premas ___________ in developing
___________ proteins for vaccine
development. Such proteins are _____
“difficult to _______ proteins” (DTE-Ps).
___ innovative D-Crypt platform is
optimized for highyield __________ of
DTE-Ps, __________, or in combination.
Through _ partnership with Akers
Biosciences, Premas is leveraging ______ to develop a multicomponent
recombinant protein vaccine _______
COVID-19.